Chimovits Erez, DIR, reported an open-market or private purchase at ADARx Pharmaceuticals, Inc. involving 61516.000000 shares for an estimated $1045772.00. Reported holdings after the transaction were 9292025.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a high positive filing-only score. It may deserve closer research, but it is not an investment recommendation.
Form 4 relationship flags and nearby filing context
No officer title
Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 1-for-1.17…
Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
These securities are held directly by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("Israel GP") is the general partner of OIP II. OrbiMed Advisors Israel II Limited ("Advis…
Each of the Reporting Person, Israel GP, and Advisors Israel disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, a…
0 other filings
0 recent txs